HDAC7 Inhibits Cell Proliferation Via NudCD1/GGH Axis in Triple-negative Breast Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2023 Jan 2

PMID 36589669

Authors

Mengdi Zhu

Nianqiu Liu

Jinna Lin

Jingru Wang

Hongna Lai

Yujie Liu

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer. In the absence of effective molecular markers for TNBC, there is an urgent clinical need for promising therapeutic target for TNBC. Histone deacetylases (HDACs), key regulators for chromatin remodeling and gene expression, have been suggested to play critical roles in cancer development. However, little is known ~the functions and implications of HDACs in TNBC treatment in the future. By analyzing the expression and prognostic significance of HDAC family members in TNBC through TCGA and METABRIC databases, HDAC7 was found to be downregulated in TNBC samples and the survival of patients with lower expression of HDAC7 was shorter. Furthermore, HDAC7 was negatively associated with NudC domain containing 1 (NudCD1) and γ-glutamyl hydrolase (GGH). Loss of NudCD1 or GGH predicted improved overall survival time (OS) of patients with TNBC. experiments showed that silencing of HDAC7 enhanced TNBC cell proliferation, while overexpression HDAC7 inhibited TNBC cell proliferation. The results of functional experiments confirmed that HDAC7 negatively modulated GGH and NudCD1 expression. Furthermore, decrease of NudCD1 or GGH inhibited cell proliferation. Notably, the HDAC7-NudCD1/GGH axis was found to be associated with NK cell infiltration. Overall, the present study revealed a novel role of HDAC7-NudCD1/GGH axis in TNBC, which might provide a promising treatment strategy for patients with TNBC.

Citing Articles

The Epigenetic Modifiers HDAC2 and HDAC7 Inversely Associate with Cancer Stemness and Immunity in Solid Tumors.

Maciejewski K, Giers M, Oleksiewicz U, Czerwinska P Int J Mol Sci. 2024; 25(14).

PMID: 39063083 PMC: 11277355. DOI: 10.3390/ijms25147841.

HDAC7: a promising target in cancer.

Liu C, Zheng D, Pu X, Li S Front Oncol. 2024; 14:1327933.

PMID: 38487728 PMC: 10939994. DOI: 10.3389/fonc.2024.1327933.

Small molecule agents for triple negative breast cancer: Current status and future prospects.

Ou Y, Wang M, Xu Q, Sun B, Jia Y Transl Oncol. 2024; 41:101893.

PMID: 38290250 PMC: 10840364. DOI: 10.1016/j.tranon.2024.101893.

Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research.

Witt B, Tollefsbol T Life (Basel). 2023; 13(12).

PMID: 38137912 PMC: 10744609. DOI: 10.3390/life13122311.

References

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi M, Moradi-Kalbolandi S . Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020; 84:106535. DOI: 10.1016/j.intimp.2020.106535. View

Keenan T, Tolaney S . Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2020; 18(4):479-489. DOI: 10.6004/jnccn.2020.7554. View

Dowling C, Hollinshead K, Di Grande A, Pritchard J, Zhang H, Dillon E . Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Sci Adv. 2021; 7(3). PMC: 7810372. DOI: 10.1126/sciadv.abc4897. View

Huang J, Ling K . EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys acetylation in the gene promoter and enhancers. Oncol Lett. 2017; 14(5):5735-5742. PMC: 5661363. DOI: 10.3892/ol.2017.6912. View

Yu C, Qi H, Zhang Y, Zhao W, Wu G . Elevated Expression of Gamma-Glutamyl Hydrolase Is Associated With Poor Prognosis and Altered Immune Signature in Uterine Corpus Endometrial Carcinoma. Front Genet. 2022; 12:764194. PMC: 8785095. DOI: 10.3389/fgene.2021.764194. View

Wang Z, Chen Z, Jiang G, Wu Y, Liu T, Yi Y . Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells. Cell Signal. 2016; 28(5):506-515. DOI: 10.1016/j.cellsig.2016.02.006. View

Ho T, Chan A, Ganesan A . Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. J Med Chem. 2020; 63(21):12460-12484. DOI: 10.1021/acs.jmedchem.0c00830. View

Ma W, Sun J, Xu J, Luo Z, Diao D, Zhang Z . Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020; 10(6):2463-2478. PMC: 7052901. DOI: 10.7150/thno.38973. View

Lei Y, Liu L, Zhang S, Guo S, Li X, Wang J . Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation. Mol Cancer. 2017; 16(1):170. PMC: 5681774. DOI: 10.1186/s12943-017-0736-2. View

10.

Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L . Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012; 11(4):973-83. DOI: 10.1158/1535-7163.MCT-11-0979. View

11.

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

12.

da Silva J, Nunes N, Izetti P, Gomes de Mesquita G, de Melo A . Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 2020; 145:102855. DOI: 10.1016/j.critrevonc.2019.102855. View

13.

Chiu H, Yeh Y, Wang Y, Huang W, Ho S, Lin P . Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Mol Cancer. 2016; 15(1):46. PMC: 4902929. DOI: 10.1186/s12943-016-0531-5. View

14.

Hesham H, Lasheen D, Abouzid K . Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. Med Res Rev. 2018; 38(6):2058-2109. DOI: 10.1002/med.21505. View

15.

Oba T, Ono M, Matoba H, Uehara T, Hasegawa Y, Ito K . HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells. Breast Cancer Res Treat. 2021; 186(1):37-51. DOI: 10.1007/s10549-020-06033-2. View

16.

Barneda-Zahonero B, Collazo O, Azagra A, Fernandez-Duran I, Serra-Musach J, Islam A . The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell Death Dis. 2015; 6:e1635. PMC: 4669785. DOI: 10.1038/cddis.2014.594. View

17.

Palmieri D, Lockman P, Thomas F, Hua E, Herring J, Hargrave E . Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res. 2009; 15(19):6148-57. PMC: 7356672. DOI: 10.1158/1078-0432.CCR-09-1039. View

18.

Uzelac B, Krivokuca A, Susnjar S, Milovanovic Z, Supic G . Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients. Genet Test Mol Biomarkers. 2021; 25(3):227-235. DOI: 10.1089/gtmb.2020.0138. View

19.

Caslini C, Hong S, Ban Y, Chen X, Ince T . HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene. 2019; 38(39):6599-6614. DOI: 10.1038/s41388-019-0897-0. View

20.

Guo K, Ma Z, Zhang Y, Han L, Shao C, Feng Y . HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway. J Exp Clin Cancer Res. 2022; 41(1):91. PMC: 8915541. DOI: 10.1186/s13046-022-02266-9. View